Lower dose of insulin-sensitizing drug benefits patients with Type 2 diabetes

Published April 1, 2022

An article in Technology.org reports on a study co-authored by Paresh Dandona, MD, PhD, SUNY Distinguished Professor of Medicine in the Jacobs School of Medicine and Biomedical Sciences, on how lower doses of insulin-sensitizing drug can patients with Type 2 diabetes. Dandona says this recommendation stems directly from the findings of the Insulin Resistance Intervention in Stroke (IRIS) trial. “Unfortunately, many clinicians are reluctant to use pioglitazone because of adverse effects, particularly weight gain and edema, and the drug is seldom prescribed by neurologists in their stroke patients,” he says. The study was also reported on in MedicalXpress.